-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Didanosine (DDI)
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/69655-05-6.gif)
| Category | Reverse Transcriptases (RTs) |
| CAS | 69655-05-6 |
| Description | Didanosine is a reverse transcriptase inhibitor with an IC50 of 0.49 μM. |
Product Information
| Synonyms | 2',3'-Dideoxyinosine; NSC 612049; DDI; BMY 40900; Dideoxyinosine; Videx; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one |
| IUPAC Name | 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one |
| Molecular Weight | 236.23 |
| Molecular Formula | C10H12N4O3 |
| Canonical SMILES | C1CC(OC1CO)N2C=NC3=C2NC=NC3=O |
| InChI | InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1 |
| InChIKey | BXZVVICBKDXVGW-NKWVEPMBSA-N |
| Boiling Point | 644.5±45.0°C at 760 mmHg |
| Melting Point | >216°C (dec.) |
| Flash Point | 275.0±32.9 °C |
| Purity | ≥95% |
| Density | 1.8±0.1 g/cm3 |
| Solubility | Soluble in Methanol (Slightly), Water (Slightly, Sonicated) |
| Appearance | White to Off-White Solid |
| Application | Anti-hiv agents; antimetabolites; reverse transcriptase inhibitors |
| Storage | Store at -20°C |
| Complexity | 348 |
| Exact Mass | 236.09094026 |
| Index Of Refraction | 1.798 |
| In Vitro | Didanosine is converted by cellular enzymes to the active antiviral metabolite dideoxyadenosine triphosphate (dd-ATP) and the intracellular half life of dd-ATP varies from 8-24 hours. Didanosine shows antiretroviral activity with IC50 value of 0.24-0.6 mg/L for HIV infection. Didanosine (5, 10, 50, 100 ug/ml; 24, 48 h) shows no significant inhibition of cell proliferation in IEC-6 cells. |
| In Vivo | Didanosine (100, 150 mg/kg; p.o.; daily for 7 days) decreases the length of duodenal and in jejunal villus in mouse. |
| PSA | 93.03000 |
| Target | HIV; Reverse Transcriptase |
| Vapor Pressure | 0.0±1.5 mmHg at 25°C |
| XLogP3-AA | -1.2 |
